Oncosnacks 13: Pancreatic Cancer - NAPOLI-3 Trial Update

IN BREAKING NEWS... Or not really, as we are a bit late to the party. But in honour of liposomal irinotecan's recent approval by the Federal Drugs Administration, we thought we would take another look at the NAPOLI-3 trial. The first potentially practice-changing update to the treatment of advanced pancreatic cancer arguably in more than a decade, the combination of liposomal irinotecan with 5-fluorouracil and oxaliplatin proved itself superior (spoiler alert) to the established combination of gemcitabine and nab-paclitaxel. Will this practically change practice for our patients? The answer, for Australia at least, is a resounding maybe. Listen on for all the juicy details, and the return of OftiM Newsreader "Walter Fernando-Cronkite."